bioAffinity Technologies, Inc. (BIAF)
NASDAQ: BIAF · Real-Time Price · USD
1.880
-0.110 (-5.53%)
At close: May 15, 2026, 4:00 PM EDT
1.870
-0.010 (-0.53%)
After-hours: May 15, 2026, 7:20 PM EDT
bioAffinity Technologies Revenue
bioAffinity Technologies had revenue of $1.35M in the quarter ending March 31, 2026, a decrease of -27.09%. This brings the company's revenue in the last twelve months to $5.66M, down -35.75% year-over-year. In the year 2025, bioAffinity Technologies had annual revenue of $6.16M, down -34.18%.
Revenue (ttm)
$5.66M
Revenue Growth
-35.75%
P/S Ratio
1.49
Revenue / Employee
$99,296
Employees
57
Market Cap
8.45M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.16M | -3.20M | -34.18% |
| Dec 31, 2024 | 9.36M | 6.83M | 269.68% |
| Dec 31, 2023 | 2.53M | 2.53M | 52,627.44% |
| Dec 31, 2022 | 4.80K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Inotiv | 507.36M |
| MDxHealth | 110.97M |
| FONAR | 105.34M |
| Exagen | 68.38M |
| XWELL | 29.21M |
| Precipio | 24.05M |
| iSpecimen | 1.93M |
| Quantum Cyber | 537.08K |
BIAF News
- 4 days ago - BioAffinity says CyPath Lung test unit sales achieved monthly record in April - TheFly
- 4 days ago - bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026 - Business Wire
- 8 days ago - BioAffinity Technologies reports Q1 EPS (81c) vs. ($4.80) last year - TheFly
- 8 days ago - bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung - Business Wire
- 16 days ago - BioAffinity Technologies files to sell 497,483 shares of common stock for holder - TheFly
- 18 days ago - BioAffinity Technologies launches new study to expand use of CyPath lung tech - TheFly
- 18 days ago - bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment - Business Wire
- 4 weeks ago - BioAffinity Technologies releases clinical case on CyPath Lung - TheFly